• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulet’s closed-loop insulin delivery algorithm succeeds in feasibility study

February 13, 2018 By Sarah Faulkner

Insulet omnipodThe algorithm used in Insulet‘s (NSDQ:PODD) closed-loop insulin delivery system performed well in a 58-patient safety and feasibility study, according to a study published today in Diabetes Technology & Therapeutics.

Insulet’s device, which is still in development, combines an insulin dosing algorithm, the OmniPod insulin patch pump and Dexcom‘s (NSDQ:DXCM) continuous glucose monitor into one system that automates insulin delivery based on the user’s blood sugar levels.

In the single-arm trial, participants managed their diabetes at home using their usual technologies for one week, followed by a 36-hour inpatient stay using the investigational OmniPod hybrid closed-loop system.

The system’s algorithm was originally developed at the University of California at Santa Barbara and is designed to make insulin-dosing decisions every five minutes based on values from Dexcom’s CGM.

“This multicenter, inpatient feasibility study demonstrated that the OmniPod personalized MPC algorithm performed well and was safe during day and night use over 36 h in adult, adolescent, and pediatric patients with Type I diabetes,” the researchers wrote. “Positive glycemic outcomes were consistently observed across age groups that included adolescents who are typically challenged by insulin resistance and children as young as 6 years of age with enhanced insulin sensitivity.”

The study’s authors noted that the algorithm was especially useful for controlling participants’ blood sugar at night – patients’ blood glucose levels remained within the target range more than 85% of the time.

The trial’s results are limited by a number of factors. The Insulet-funded study was short and held in a supervised setting, where healthcare workers managed the systems instead of the patients. Also, as the researchers noted, they did not design the trial to include a control arm.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: DexCom Inc., Insulet

IN CASE YOU MISSED IT

  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS